ArticleDer Urologe. Ausg. A2022

[Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].

Isabel Heidegger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.